Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.13 +0.02 (+0.14%)
Streaming Delayed Price Updated: 2:10 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
From Takeda Pharmaceutical Company Limited
Via Business Wire
Understanding Takeda Pharmaceutical's Unusual Options Activity
Takeda Pharmaceutical (NYSE:TAK) shares experienced unusual ... 
Via Benzinga
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
From Takeda Pharmaceutical Company Limited
Via Business Wire
Timeless Values, Life-Changing Progress
SOURCE: Takeda 
Via 3BL Media
Full News Day
The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier. 
Via Talk Markets
Topics Energy
Takeda's Narcolepsy Candidate Gets FDA Breakthrough Therapy Tag
The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's (NYSE: TAK) TAK-994 for excessive daytime sleepiness (EDS... 
Via Benzinga
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
From Takeda Pharmaceutical Company Limited
Via Business Wire
XBIO Stock: Xenetic Soars on Private Placement Announcement
XBIO stock is continuing a heck of a week. Just days after it was boosted by Takeda's expansion news, it's looking at a big private sale. 
Via InvestorPlace
Containment Plan
Today the US decided to cut China risks. 
Via Talk Markets
“Claw-Back” day
The rally was just as irrational as the selloff. 
Via Talk Markets
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna Extends Rally With Expanded Japanese COVID-19 Vaccine Supply Deal
Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight... 
Via Benzinga
Japan To Buy Additional 50M Doses Of Moderna COVID-19 Vaccine
Moderna Inc (NASDAQ: MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) will... 
Via Benzinga
Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
Selloff Round 3
Stocks fell across the board in foreign countries, except for Britain which was upbeat. 
Via Talk Markets
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Recovery Friday
The big winners this week were Financials. 
Via Talk Markets
Sell Sell Sell
Today the inevitable reversal of wild gains overtook Wall Street, echoing what occurred in major foreign markets Monday. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
End Of June
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Summer Friday
The stock market tried for another record after yesterday's late blowout over the infrastructure deal. 
Via Talk Markets
Crazy Thursday
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
Wednesday Is A Normal Day
Meme stocks Gamestop and Torchlight Energy both did share sales to cash in on their share price rises. 
Via Talk Markets
The First Day Of Summer And Prime Day
The bull is back in business today. 
Via Talk Markets
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Cathie Wood Sells Another $6.8M In 3D Printing Marketplace Shapeways' SPAC
Cathie Wood-led Ark Investment Management on Thursday sold 679,335 shares, estimated to be worth about $6.8 million, in blank-check firm Ga... 
Via Benzinga
Blueprint for Access to Innovative Healthcare Episode 2: Screening
SOURCE: Takeda 
Via 3BL Media
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.